Allison Whitten, PhD
Allison Whitten earned her PhD from Vanderbilt University in 2018 and continued her scientific training at Vanderbilt as a National Institute of Biomedical Imaging and Bioengineering (NIBIB) Postdoctoral Fellow. Her PhD and postdoctoral studies investigated the neurobiological causes of language impairments in neurological disorders. In 2020, she was awarded an AAAS Mass Media Fellowship to write for Discover Magazine. Her work has also appeared in WIRED, Quanta Magazine, Ars Technica, and more.
Articles by Allison Whitten, PhD
| 6 min read
Judy Sebolt-Leopold and her team at MEKanistic Therapeutics developed a single molecule targeting two kinase enzymes that drive resistance to cancer therapies.
| 6 min read
Most cancer cells have the wrong number of chromosomes, known as aneuploidy. Scientists are finding ways to target this flaw with new treatments.
| 10+ min read
GLP-1 agonists have transformed the treatment of type 2 diabetes and obesity, but they come with side effects. Physicians say the benefits outweigh the risks.
| 2 min read
Researchers revealed for the first time that CAR T cells can transfer their CAR molecules to regular T cells in a process known as trogocytosis.
| 8 min read
Lundbeck Therapeutics is testing a monoclonal antibody that targets a novel neuropeptide in a Phase 2b clinical trial.
| 4 min read
Pfizer researchers are developing new treatments to target breast cancer tumors that flourish in the presence of hormones.
| 2 min read
Using a sheep model, researchers developed an injectable biomaterial that interacts with nearby cells and recruits them to make new cartilage.
| 4 min read
Industry leaders name the clinical trials and developments they’re most excited to see in the new year.
| 5 min read
Industry leaders predict the most exciting advances in drug discovery and development in the coming year.
| 6 min read
Researchers discovered that a blood clotting protein, fibrinogen, harms brain development during bleeds in preterm infants.
| 8 min read
New gene therapies in clinical trials seek to treat Alzheimer’s disease and heal the brain with a dose of helpful genetic material.
| 6 min read
Scores of neurons are already dead by the time Parkinson’s disease is usually diagnosed. Scientists aim to identify patients earlier and intervene before it’s too late.
